2.42
Dare Bioscience Inc stock is traded at $2.42, with a volume of 95,008.
It is up +0.83% in the last 24 hours and up +2.11% over the past month.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
See More
Previous Close:
$2.40
Open:
$2.38
24h Volume:
95,008
Relative Volume:
0.07
Market Cap:
$21.85M
Revenue:
-
Net Income/Loss:
$-30.16M
P/E Ratio:
-7.1176
EPS:
-0.34
Net Cash Flow:
$-39.49M
1W Performance:
-5.84%
1M Performance:
+2.11%
6M Performance:
-25.54%
1Y Performance:
-29.03%
Dare Bioscience Inc Stock (DARE) Company Profile
Name
Dare Bioscience Inc
Sector
Industry
Phone
858-926-7655
Address
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
DARE
Dare Bioscience Inc
|
2.42 | 21.24M | 0 | -30.16M | -39.49M | -0.34 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Dare Bioscience Inc Stock (DARE) Latest News
Dare Bioscience shares fall 1.61% premarket after launching consumer awareness campaign for DARE to PLAY Sildenafil Cream. - AInvest
Daré Bioscience and Rosy Wellness Launch First Phase of - GlobeNewswire
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream - Yahoo Finance
Daré Bioscience Meets Nasdaq Equity Requirement - TipRanks
UPDATEDaré Bioscience to Host August 6 Webinar: The DARE - GlobeNewswire
Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ DifferenceThe Sildenafil Cream That Raises the Bar - GlobeNewswire
Revolutionary Female Viagra Cream: First-Ever FDA-Approved Sildenafil Treatment for Women Coming This Year - Stock Titan
Daré Bioscience Reports Positive Contraception Trial Results as Smart Drug Delivery Platform Shows Broader Potential - Femtech Insider
Hold Rating on Daré Bioscience: Balancing Promising Product Development with Financial Uncertainties - TipRanks
Dare Bioscience stock holds Buy rating at H.C. Wainwright on positive trial data - Investing.com Canada
3 Penny Stocks to Watch Now, 7/15/25 - TipRanks
Daré Bioscience reports positive interim results for hormone-free contraceptive - Investing.com Australia
Small Healthcare Stocks Enjoy Big Wins On Deal News - Finimize
Dare Bioscience Surges to 200th in Market Rankings with $47.4 Million Turnover - AInvest
Douglas Tsao Recommends ‘Buy’ for Daré Bioscience: Ovaprene’s Promising Potential and Financial Prospects - TipRanks
Crude Oil Moves Lower; Daré Bioscience Shares Jump - inkl
Dare reports interim safety, efficacy results from Phase 3 trial of Ovaprene - TipRanks
Daré Bioscience stock soars after positive interim Phase 3 contraceptive results - Investing.com India
Daré Bioscience Soars 250% on Positive Ovaprene Trial Data - Wall Street Pit
Dare Bioscience’s Unforeseen Stock Skyward Leap - StocksToTrade
US Stocks Edge Lower; Fastenal Posts Upbeat Earnings - Benzinga
Dare Bioscience Reflects on Grant Milestone - timothysykes.com
Daré Bioscience reports positive interim results for hormone-free contraceptive By Investing.com - Investing.com South Africa
Why Is Daré Bioscience Stock (DARE) Up 240% Today? - TipRanks
Dare Bioscience Announces Positive Results From Hormone-Free Contraceptive Trial; Shares Surge - MarketScreener
Daré Bioscience Announces Positive Phase 3 Trial Results - TipRanks
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive - The Manila Times
Daré Bioscience Announces Positive Interim Results from Phase 3 Trial of Hormone-Free Contraceptive Ovaprene® - Quiver Quantitative
Dare Bioscience Plunges 11.33% Amid Market Shifts - AInvest
Daré Bioscience receives $6 million installment for contraceptive device - Investing.com Australia
Daré Bioscience Receives $6 Million Non-Dilutive Grant - GlobeNewswire
Dare Bioscience Sees Stock Surge Amid Strategic Collaborations - StocksToTrade
Daré Bioscience receives $6 million installment for contraceptive device By Investing.com - Investing.com South Africa
Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders - GlobeNewswire
Daré's Smart Drug Delivery Platform Secures $6M Grant, Eyes Expansion into $B Obesity Market - Stock Titan
Dare Bioscience shareholders approve board nominees and stock plan amendment - Investing.com Nigeria
Daré Bioscience Stockholder Meeting Approves Key Proposals - TipRanks
Daré Bioscience Gains Nasdaq Compliance Extension Approval - TipRanks
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders | DARE Stock News - GuruFocus
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders - GlobeNewswire
Daré Bioscience Stockholders Must Vote by July 8 for Crucial Annual Meeting - Stock Titan
Daré Bioscience Announces Corporate Presentation for Investors - TipRanks
Brokers Offer Predictions for Daré Bioscience Q1 Earnings - Defense World
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
H.C. Wainwright maintains Buy rating on Dare Bioscience stock By Investing.com - Investing.com Canada
Daré Bioscience partners with Rosy Wellness for new women’s health cream By Investing.com - Investing.com South Africa
Daré Bioscience and Rosy Wellness Announce Strategic - GlobeNewswire
Daré Bioscience partners with Rosy Wellness for new women’s health cream - Investing.com
Dare Bioscience (DARE) Joins Forces with Rosy Wellness for Product Campaign | DARE Stock News - GuruFocus
Dare Bioscience Inc Stock (DARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):